NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.

MLA

Lee, Eudocia Q., et al. “NRG/RTOG 1122: A Phase 2, Double-Blinded, Placebo-Controlled Study of Bevacizumab with and without Trebananib in Patients with Recurrent Glioblastoma or Gliosarcoma.” Cancer, vol. 126, no. 12, June 2020, pp. 2821–28. EBSCOhost, https://doi.org/10.1002/cncr.32811.

APA

Lee, E. Q., Zhang, P., Wen, P. Y., Gerstner, E. R., Reardon, D. A., Aldape, K. D., deGroot, J. F., Pan, E., Raizer, J. J., Kim, L. J., Chmura, S. J., Robins, H. I., Connelly, J. M., Battiste, J. D., Villano, J. L., Wagle, N., Merrell, R. T., Wendland, M. M., & Mehta, M. P. (2020). NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer, 126(12), 2821–2828. https://doi.org/10.1002/cncr.32811

Chicago

Lee, Eudocia Q, Peixin Zhang, Patrick Y Wen, Elizabeth R Gerstner, David A Reardon, Kenneth D Aldape, John F deGroot, et al. 2020. “NRG/RTOG 1122: A Phase 2, Double-Blinded, Placebo-Controlled Study of Bevacizumab with and without Trebananib in Patients with Recurrent Glioblastoma or Gliosarcoma.” Cancer 126 (12): 2821–28. doi:10.1002/cncr.32811.